Alnylam Announces Planned Departure of Chief Business Officer, Laurence Reid, Ph.D.
December 19 2014 - 8:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi
therapeutics company, announced today that Laurence Reid, Ph.D.,
the company’s Chief Business Officer, plans to resign from the
company, effective December 31, 2014. Dr. Reid will be joining
Third Rock Ventures (TRV) as an Entrepreneur-in-Residence, and is
expected to become a Chief Executive Officer for a TRV portfolio
company in the future. Alnylam will initiate an external search to
identify a new Chief Business Officer.
“Our successful track record in business execution has been a
team effort, but I want to sincerely thank Laurence for his
leadership and outstanding contributions to the company over the
last many years. Amongst many other accomplishments, Laurence’s
business development leadership at Alnylam resulted in our
alliances with Genzyme, The Medicines Company, and Monsanto, in
addition to the acquisition of Sirna Therapeutics in our agreement
with Merck,” said John Maraganore, Ph.D., Chief Executive Officer
of Alnylam. “We wish Laurence nothing but the best, and we are very
proud to count him as one of our Alnylam alumni, expanding his
position of leadership in the biopharmaceutical industry.”
“Alnylam is a remarkable company that has pioneered the
advancement of RNAi therapeutics as a whole new class of medicines.
I feel privileged to have had the opportunity to contribute to this
effort,” said Laurence. “During my tenure, I have worked with
outstanding and passionate colleagues and external partners who
will, I believe, deliver these innovative medicines to patients and
the market in the coming years. I look forward to watching
Alnylam’s continued success, and I will remain a strong supporter
of the company, even as I move on to new opportunities.”
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel
therapeutics based on RNA interference, or RNAi. The company is
leading the translation of RNAi as a new class of innovative
medicines. In late 2014, Alnylam launched its pipeline growth
strategy for RNAi therapeutics in three strategic therapeutic areas
(STArs): Genetic Medicines, Cardio-metabolic Disease, and Hepatic
Infectious Disease. Alnylam’s Genetic Medicine STAr investigational
pipeline includes: patisiran (ALN-TTR02) targeting transthyretin
(TTR) for the treatment of TTR-mediated amyloidosis (ATTR) in
patients with familial amyloidotic polyneuropathy (FAP); revusiran
(ALN-TTRsc) targeting TTR for the treatment of ATTR in patients
with TTR cardiac amyloidosis, including familial amyloidotic
cardiomyopathy (FAC); ALN-AT3 targeting antithrombin (AT) for the
treatment of hemophilia and rare bleeding disorders (RBD); ALN-CC5
targeting complement component C5 for the treatment of
complement-mediated diseases; ALN-AS1 targeting aminolevulinic acid
synthase-1 (ALAS-1) for the treatment of hepatic porphyrias
including acute intermittent porphyria (AIP); ALN-AAT targeting
alpha-1 antitrypsin (AAT) for the treatment of AAT
deficiency-associated liver disease; ALN-TMP targeting TMPRSS6 for
the treatment of beta-thalassemia and iron-overload disorders;
ALN-GO1 targeting glycolate oxidase (GO) for the treatment of
primary hyperoxaluria type 1 (PH1); and other programs yet to be
disclosed. Alnylam’s Cardio-metabolic Disease STAr investigational
pipeline includes: ALN-PCSsc targeting PCSK9 for the treatment of
hypercholesterolemia; ALN-ANG targeting angiopoietin-like 3
(ANGPTL3) for the treatment of mixed hyperlipidemia and
hypertriglyceridemia; ALN-AC3 targeting apolipoprotein C-3 (apoC3)
for the treatment of hypertriglyceridemia; ALN-AGT targeting
angiotensinogen (AGT) for the treatment of hypertensive disorders
of pregnancy (HDP), including preeclampsia; and other programs yet
to be disclosed. Alnylam’s Hepatic Infectious Disease STAr
investigational pipeline includes: ALN-HBV targeting the hepatitis
B virus (HBV) genome for the treatment of HBV infection; ALN-HDV
targeting the hepatitis delta virus (HDV) genome for the treatment
of HDV infection; ALN-PDL targeting programmed death ligand 1
(PD-L1) for the treatment of chronic liver infections; and other
programs yet to be disclosed. The company’s demonstrated commitment
to RNAi therapeutics has enabled it to form major alliances with
leading companies including Merck, Medtronic, Novartis, Biogen
Idec, Roche, Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline,
Ascletis, Monsanto, and The Medicines Company. In early 2014,
Alnylam and Genzyme, a Sanofi company, formed a multi-product
geographic alliance on Alnylam's genetic medicine programs in the
rare disease field. Specifically, Alnylam will lead development and
commercialization of programs in North America and Europe, while
Genzyme will develop and commercialize products in the rest of
world. In addition, Alnylam and Genzyme will co-develop and
co-commercialize revusiran in North America and Europe. In March
2014, Alnylam acquired Sirna Therapeutics, a wholly owned
subsidiary of Merck. In addition, Alnylam holds an equity position
in Regulus Therapeutics Inc., a company focused on discovery,
development, and commercialization of microRNA therapeutics.
Alnylam scientists and collaborators have published their research
on RNAi therapeutics in over 200 peer-reviewed papers, including
many in the world’s top scientific journals such as Nature, Nature
Medicine, Nature Biotechnology, Cell, New England Journal of
Medicine, and The Lancet. Founded in 2002, Alnylam maintains
headquarters in Cambridge, Massachusetts. For more information,
please visit www.alnylam.com.
Alnylam Forward-Looking Statements
Various statements in this release concerning Alnylam’s future
expectations, plans and prospects, including without limitation,
Alnylam’s views with respect to the potential for RNAi
therapeutics, its expectations regarding its STAr pipeline growth
strategy, and its plans regarding commercialization of RNAi
therapeutics, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including, without limitation,
Alnylam's ability to discover and develop novel drug candidates and
delivery approaches, successfully demonstrate the efficacy and
safety of its drug candidates, the pre-clinical and clinical
results for its product candidates, which may not support further
development of product candidates, actions of regulatory agencies,
which may affect the initiation, timing and progress of clinical
trials, obtaining, maintaining and protecting intellectual
property, Alnylam’s ability to enforce its patents against
infringers and defend its patent portfolio against challenges from
third parties, obtaining regulatory approval for products,
competition from others using technology similar to Alnylam’s and
others developing products for similar uses, Alnylam's ability to
manage operating expenses, Alnylam’s ability to obtain additional
funding to support its business activities and establish and
maintain strategic business alliances and new business initiatives,
Alnylam’s dependence on third parties for development, manufacture,
marketing, sales and distribution of products, the outcome of
litigation, and unexpected expenditures, as well as those risks
more fully discussed in the “Risk Factors” filed with Alnylam's
most recent Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission (SEC) and in other filings that Alnylam
makes with the SEC. In addition, any forward-looking statements
represent Alnylam's views only as of today and should not be relied
upon as representing its views as of any subsequent date. Alnylam
explicitly disclaims any obligation to update any forward-looking
statements.
Alnylam Pharmaceuticals, Inc.Cynthia Clayton,
617-551-8207Vice President, Investor Relations and Corporate
CommunicationsorMedia:SpectrumLiz Bryan, 202-955-6222 x2526
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024